0HFR Stock Overview
A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Anavex Life Sciences Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$8.32 |
52 Week High | US$14.45 |
52 Week Low | US$3.60 |
Beta | 0.82 |
1 Month Change | -5.66% |
3 Month Change | -4.82% |
1 Year Change | 86.57% |
3 Year Change | -11.00% |
5 Year Change | n/a |
Change since IPO | 175.54% |
Recent News & Updates
Recent updates
Shareholder Returns
0HFR | GB Biotechs | GB Market | |
---|---|---|---|
7D | -2.9% | 0.1% | 0.9% |
1Y | 86.6% | -14.2% | 0.7% |
Return vs Industry: 0HFR exceeded the UK Biotechs industry which returned -14.2% over the past year.
Return vs Market: 0HFR exceeded the UK Market which returned 0.7% over the past year.
Price Volatility
0HFR volatility | |
---|---|
0HFR Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 9.3% |
Market Average Movement | 5.8% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0HFR has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0HFR's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 42 | Chris Missling | www.anavex.com |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company’s lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer’s disease and Parkinson’s disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer’s disease.
Anavex Life Sciences Corp. Fundamentals Summary
0HFR fundamental statistics | |
---|---|
Market cap | US$710.29m |
Earnings (TTM) | -US$47.14m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.1x
P/E RatioIs 0HFR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HFR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$47.14m |
Earnings | -US$47.14m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
Earnings per share (EPS) | -0.55 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did 0HFR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/19 12:49 |
End of Day Share Price | 2025/05/16 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anavex Life Sciences Corp. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Caroline Palomeque | Berenberg |
Jason Kolbert | D. Boral Capital LLC. |
Christopher James | FBR Capital Markets & Co. |